Case Report
selected patients even with very advanced age. Herein, we report a 76-year-old woman with AML who received RIC and HSCT following the reinduction of relapsed disease, which resulted in successful engraftment and durable remission. To the best of our knowledge, she is the oldest patient to have received an allogeneic HSCT in Taiwan to date.
case rePort
A 76-year-old woman with a medical history of diabetes mellitus and hypertension presented with dry cough and sore throat for 2 months. Additional symptoms included general malaise, fatigue, and poor appetite. She initially sought help at a local clinic and was given steroids and empirical antibiotics. Despite this treatment, her symptoms persisted and she was subsequently referred to a tertiary medical center for further evaluation.
A physical examination revealed purpura on bilateral forearms, and a hemogram revealed white blood cell: 2060/µL, platelet: 43,000/µL, hemoglobin: 7.8 g/dL, neutrophil: 6%, lymphocytes: 51%, monocytes: 6%, blasts: 15%, and atypical lymphocytes: 12%. Renal and liver function tests, coagulation tests, and electrolytes were within normal range. Bilateral ground glass-like infiltration over the lower lungs was visible on a chest X-ray, and a subsequent chest computed tomography showed multiple consolidation over bilateral lower lungs. Fungal pneumonia was suspected, and she was admitted to receive intravenous antibiotic/antifungal treatment and to undergo evaluation for pancytopenia.
Bone marrow aspiration smear revealed hypercellularity with abundant blasts [ Figure 1 ], and bone marrow biopsy showed a high proportion of blasts without differentiating features. Cytogenetics demonstrated a normal karyotype, and multicolor flow cytometry identified blasts with positive CD34/HLA-DR/ CD13/CD33/partial CD15/cytoplasmic myeloperoxidase, confirming the diagnosis of AML, French-American-British classification M1. She was categorized as being at intermediate risk, according to the European Leukemia Net (ELN) risk stratification.
The patient then received induction chemotherapy with "I3A7" following adequate infection control. She endured induction chemotherapy despite the subsequent confirmation of invasive pulmonary aspergillosis and went into complete remission. The fungal pneumonia was managed successfully with micafungin and later posaconazole.
The patient then underwent four cycles of high-dose cytarabine consolidation, and follow-up flow cytometry showed residual leukemic cells. Gross relapse occurred 6 months following completion of consolidation therapy with the onset of refractory pancytopenia.
With a fair performance status, relatively low comorbidity, good tolerance to previous treatment, and a strong personal preference for curative treatment, intensive therapy was considered. More specifically, her HCT-specific comorbidity index (HCT-CI) was 2 and Karnofsky performance status was 90, inferring a relatively low transplant-related risk. Hence, she received reinduction with the "FLAG" regimen, and a search for potential allogeneic stem cell donors was undertaken. An HLA fully matched sibling donor was identified (her 60-year-old sister) with an obstetric history of G2P2A0 [ Table 1 ]. The patient successfully went into second complete remission after reinduction, and an allogeneic stem cell transplantation was arranged. A RIC regimen was designed for the patient with fludarabine, busulfan, and cyclophosphamide (fludarabine 30 mg/m 2 × 5 days, busulfan 3.2 mg/kg × 2 days, and cyclophosphamide 30 mg/kg × 1 day). A stem cell dose of 6.46 × 10 6 /kg was infused, and antithymocyte immunoglobin 2.5 mg/kg was administered on day 2 (D2) to D1. Graft-versus-host disease (GVHD) prophylaxis included daily cyclosporine infusion (3 mg/kg) initiated from D1, adjusted according to the trough level, and methotrexate infusion on D1, D3, D6, and D11 (15 mg/m 2 for D1 and 10 mg/m 2 for D3, D6, and D11). She tolerated the regimen well with no significant infection during the neutropenic stage and only Grade I diarrhea and fatigue during the course. Successful engraftment was achieved on D11, and no GVHD was observed up to D119. Follow-up flow cytometry and bone marrow aspiration smear confirmed successful trilineage engraftment with no residual disease. The standard short tandem repeat genotyping analysis showed complete chimerism.
dIscussIon
The treatment of AML in older patients has undergone rapid changes in the past decade. Earlier studies repeatedly reported that increasing age was a significant risk factor for worse outcomes after HCT in patients with AML, [12, 13] which led to the adoption of age restrictions for HSCT in the earlier AML treatment guidelines. However, with the higher incidence of AML in patients in the latter decades of life and the worse prognosis in elderly AML patients, such age restrictions severely limited the treatment options for these patients.
With the advent of RIC regimens, HSCT has been extended to an increasingly older population, and the median age of patients with myelodysplastic syndrome or AML who have received HSCT has increased by 20 years since the 1980s. [10] In a meta-analysis by Rashidi et al., the outcomes of HSCT with RIC in elderly patients in 13 studies were analyzed. [14] The pooled analysis showed a 3-year relapse-free survival rate of 35% in patients over 60 years of age, suggesting that RIC is a viable treatment option in older patients with AML. Several retrospective analyses have demonstrated that increased age alone was not associated with worse NRM or OS, further challenging the use of age alone as a criterion in patient selection. [9, 11, 13] Many of the aforementioned studies that explored the impact of age on HSCT outcomes in AML patients selected patients older than 60 or 65 years of age; [9, 11, 14] however, data on AML patients older than 70 years receiving HSCT in the setting of RIC are more limited. Several recent studies have addressed this issue and examined the outcomes of HSCT in hematological malignancies in patients over 70 years of age, and the results have been consistent with younger populations with a 2-year progression-free survival of 32%-39%. [15, 16] This suggests that selected patients over 70 years of age with hematological malignancies should also be considered for HSCT.
Taken together, these findings highlight the relevance of patient selection for HCT in the elderly. Several tools have been developed to stratify the risk of transplantation and evaluate the suitability of patients for HSCT, including the HCT-CI scoring system which is used to predict transplant-related toxicity and is now frequently used for the pretransplant assessment. [17] However, the HCT-CI is insufficient with regard to incorporating all relevant parameters in elderly patients. Consequently, several trials have investigated the prognostic significance of geriatric assessment in this scenario, which encompassed assessment of frailty, cognition, function status, nutrition, and socioeconomic status, all of which may ultimately impact the patient's outcome. [18, 19] The potential use of geriatric assessment scales in guiding patient selection for HCT in the elderly appears to be promising; however, further validation is required.
Our case was a 76-year-old woman who received HCT with RIC after the reinduction of relapsed AML. She endured the transplantation process without significant complications or GVHD and resulted in fair disease control. In summary, this case underscores the feasibility of HCT in selected patients with very advanced age (>70 years) and its potential benefit for these patients. HCT should be considered and evaluated in all indicated AML patients regardless of age.
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